Abstract To describe a rare association between rheumatoid arthritis (RA)
Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disorder not confined to the joints. Neurologic manifestations are detected in 40% of RA and include different form of peripheral neuropathy, such as mononeuritis multiplex or sensorimotor polyneuropathy, compressive cervical myelopathy and central or peripheral nervous system involvement mainly secondary to vasculitis. Different drugs commonly used for treatment may induce neurologic complications. The development of anti-tumor necrosis factor alpha (TNFa) therapy is the most significant achievement in the treatment of the disease to date. Among the serious potential side effects, the onset of neurologic disease, including demyelinating and multiple sclerosis (MS)-like syndrome, has been reported [1] [2] [3] [4] [5] [6] .
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disease. Loss of pyramidal and anterior horn motor neurons leads to progressive limb weakness, disability, dysarthria, dysphagia, and respiratory insufficiency with a progressive fatal course. The incidence of ALS ranges between 1.5 and 2.5 for 100,000 per year. Although there are familial cases of ALS, about 90% are sporadic and of unknown etiology [7] . Motor neuron involvement is unusual in rheumatoid arthritis. To our knowledge, only other five cases of this rare association have been previously described in literature, one of witch during anti-TNFa therapy [8] . A potential role of TNF in the pathogenesis of neurodegenerative disease is still debated. TNFa is considered as a cytokine with both neuroprotective and neurotrophic effects. However, although TNFadeficient animal models seem to be protected from motor neuron disease (MND), in trials with anti-TNFa therapy, a worsening in the disease course has been observed in MS patients, thus suggesting a causative relationship [9] .
Here we report two new cases of patients with RA who developed amyotrophic lateral sclerosis (ALS), both with bulbar syndrome, one during treatment with anti-TNa agent.
Case reports

Case 1
A 65-year-old white woman, affected by well-controlled arterial hypertension, was first seen on July 2001 at our Rheumatology Unit. She had a 10-year history of seropositive and erosive rheumatoid arthritis treated overtime with corticosteroids, gold, cyclosporine A, hydroxychloroquine and methotrexate. A TC scan recently obtained did show an initial involvement of cervical tract with slight atlo-epistrophic anterior subluxation without medullar involvement. For the persistent activity of the disease (DAS 28 6.72), she was screened for therapy with infliximab, administered at the dose of 3 mg/kg every 8 week after initial induction regimen with closer infusions. A quick improvement was noted and sustained during the following 8 months. Then, due to a flare of RA, the dosage of infliximab was increased to 5 mg/kg and a new positive clinical response was obtained. Four months after, she developed first transient and then persistent jugular tightness, dysarthria, and dysphonia. The voice became weak and nasal. Thereafter, she reported worsening rhinolalia, dysphagia for solids and liquids, and hyposthenia of lingual and respiratory muscles, especially after prolonged exercise. Anti-TNFa therapy was stopped, and a diagnostic procedure was started. Thyroid and laryngeal disease were excluded. On the physical examination, strength loss in both upper and lower limbs was evident. A complete neurologic examination did show hypotrophia of masseter and lower facial muscles deficit. Muscle enzyme and inflammatory indices were normal. Anti-acetylcholine receptor antibodies and Tensilon Ò test were negative. Additional investigations for malignancy, vasculitis, and amyloidosis were negative. Brain magnetic resonance (MR) did prove negative apart from some subcortical and bilateral nonspecific small T2-hyperintense lesions. An electromyography of the four limbs revealed a pathological denervation and reinnervation pattern. Transcranial magnetic stimulation (TMS) confirmed the upper motor neuron dysfunction with neurogenic bulbar and segmental deficit. At the follow-up, she developed additional weakness and atrophy of the forearms and tenar muscle regions. TMS showed progression of abnormalities including progressive inexcitability of central motor pathways and loss of the normal inhibitory cortical stimulation silent period. Fasciculations were also noted first in the tongue and then in the arms and thighs. A neurologic treatment program was started. Unfortunately, pharmacological therapy with riluzolo was not tolerated. Thereafter, physical and speech therapeutical approach was started but the motor weakness worsened with exitus due to ab ingestis complications and respiratory failure 5 years from diagnosis.
Case 2
The second case was a 74-year-old white woman with long-standing seropositive and erosive RA (30 years) and a secondary pulmonary fibrosis, who had failed many DMARDs approach with cyclosporine, gold, and methotrexate, this one for 10 years at least. She developed rapidly severe dysphagia and then dysphonia, weakness and weight loss. The physical examination showed fasciculations in the tongue, paralysis of XII bilateral cranic nerve, hypotrophia of masseter and lower facial muscles deficit. Also in this case, following the indications of the neurologist, the patient was underwent to a long series of clinical and instrumental analysis. The morphological study of brain and cervical tract did not show abnormalities. The electromyography and TMS revealed neurogenic abnormalities of central motor conduction and the diagnosis of MND was done. Actually the patient is still alive. Her major problems are feeding, due to severe dysphagia, and respiratory complications, related to concomitant pulmonary fibrosis and muscles weakness.
Discussion
The association between RA and ALS is very unusual. To date, only five other cases of RA and ALS occurring in the same patient have been reported [8, 10, 11] (Table 1) . In all cases, RA was erosive and symmetrical with severe functional impairment. All patients, except one, were positive for rheumatoid factor. Five cases out of seven, including our two, suffered from a long-standing RA and ALS occurred in the middle-late age, ALS started independently from the introduction of a new therapy except in two patients, our case 1 and the case reported by Dziadzio et al. [8] , where neurologic symptoms appeared after initiation and/or increase in dosage of infliximab. In the literature, another case of ALS occurred during treatment with infliximab for ankylosing spondylitis has been reported [12] . Others reports concern ALS occurring in combination with other autoimmune disease: 2 cases of systemic lupus erythematosus (SLE) [13, 14] , 1 case of scleroderma [15] , 3 cases of bollous pemphigoid [16] , and 2 cases with concomitant MS [17] . Other additional cases show ALS mimicking autoimmune diseases, e.g., Sjogren's syndrome or RA, and autoimmune disease mimicking ALS, e.g., neuropsychiatric SLE [18] [19] [20] .
The simultaneous presence of the two diseases represents a diagnostic challenge because RA may mimic some musculoskeletal symptoms of ALS and vice versa. At presentation, four of seven patients had neurologic symptoms confined to the lower limbs, foot drop, that might be confused with a peripheral neuropathy complicating RA. At onset, ALS may produce a deficit of abductor pollicis brevis and atrophy of interosseous muscles giving an aspect which can mimic the hand joint deformities of RA [20] [21] [22] [23] . On the follow-up, a more suspected bulbar syndrome developed in all patients.
The rarity of the association does not represent an evidence in favor of a shared pathophysiologic mechanism. Rather it seems to be a random association. However, a therapeutic neurotoxic side effect could be considered. There are reports of subacute reversible polyneuropathies with predominant motor symptoms resulting from gold therapy [24] . Neuromuscular symptoms have been described following chloroquine therapy, but without anterior horn cell involvement [25, 26] . Methotrexate has been associated with a variety of neurologic central nervous system (CNS) sequelae such as demyelination and necrosis [27] [28] [29] [30] [31] [32] . Although our patients did not show pertinent lesions of MTX neurotoxicity, both are taking methotrexate for long period and ongoing when ALS onset. TNFa blockers have been associated with demyelinating syndromes, also, and other forms of white matter injury (e.g. leukoencephalopathy) [1] [2] [3] [4] [5] [6] .
The role of TNF in the pathogenesis of MND and in the immune-mediated demyelination is still unexplained. Several TNF/TNF receptor actions may independently contribute or, in concert, initiate, promote or down-regulate some pathogenetic pathways of the disease [9] . Data from the literature suggest that TNF may have at least two distinct roles: neuroprotective and neurotoxic. It has been hypothesized that a perturbation of the TNF/TNF receptor system can potentially precipitate or worsen an underlying demyelination progress [33, 34] . A pro-inflammatory effect of TNFa in the initiation of experimental autoimmune encephalomyelitis (EAE) has been described. TNFa has been considered as an important mediator in MS pathogenesis, and its role has been strongly supported in several animals' models of MS. The role of TNFa in neurodegenerative disease could also be related to its ability in inducing cell death by necrosis or apoptosis [35, 36] . High circulating levels of TNFa and its soluble receptor are recognized in the blood of ALS patients, such as in RA patients [37] . However, dosing TNFa levels in the brain and spinal cord of MND mice, some authors suggested that elevated TNFa may be not the primary event in the development of MND. TNFa, also, inhibits glutamate uptake. Considering the excitotoxic hypothesis of ALS, it could be speculated that the high CNS glutamate Table 1 Cases of concomitant rheumatoid arthritis and amyotrophic lateral sclerosis reported on literature concentration induced by TNFa might contribute to motor neuron degeneration [38] . TNFa production may also be secondary to oxidative stress which is another pathogenetic mechanism proposed in ALS, as well as microglia activation [39, 40] . Alternatively, potential neuroprotective role for TNFa cannot really be excluded [9] . TNFa also leads to the activation of NFkB, which triggers the production of anti-apoptotic and neurotrophic factors. Anti-TNFa antibodies seem to be protective in animal models of MS, cerebral ischemia, brain trauma, bacterial meningitis, and cerebral malaria in which inflammation could play a role. In animal models, the neutralization of endogenous TNFa by means of over-expression of soluble receptor can reduce the death of injured motor neurons. This suggests that TNFa may play an important role in neuronal degeneration in the CNS after lesion. On other hand, it seems to be not essential for the induction of disease but may limits the evolution in a second time of its history. These two contradictory effects can perhaps be explained by the activation of two different receptors, TNFR1 for neurotoxic effect and TNFR2 for neurotrophic [41] [42] [43] [44] [45] . Surprisingly, when these concepts were transferred on clinical point of view and anti-TNFa antibodies were finally tested in MS patients, any clinically significant changes were noted, instead the number of magnetic resonance lesions increased after each treatment and the disease worsened [46] . A possible explanation is derived from the fact that the animal models, used to reproduce the acute phase of the disease and to search the target-therapy molecules, provide only a partial presentation of the human chronic pathogenetic mechanism. Some studies suggest that deficiency of this cytokine prolongs and intensifies myelindirected autoimmunity as a possible explanation for the immune activating effect of anti-TNFa treatment of MS [45] . Clinical trials are ongoing about the therapeutic use other antiTNFa agents and thalidomide, the older agent with anti-TNFa effect [47] [48] [49] . What to think of the cases of ALS occurred during treatment with TNFa blockers, 2 for RA and 1 for ankylosing spondylitis? Casual or causal association? It remains a difficult choice. Actually, we are unable to reach a final conclusion like the others authors. However, it is reasonable to insert the ALS onset during anti-TNFa therapy in the larger chapter of neurologic side effects of this drug class [50] . It is possible that the interference on the balance between TNFa neuroprotective and neurotoxic effects can determine the development or progress of ASL.
In conclusion, there are very few reports of concurrent ALS and RA, and the possibility of a coincidental association must be raised. The major point is represented by the diagnostic difficulties in the identification of ALS in patients with another chronic disease with musculo-skeletal symptoms as RA. A potential neurotoxic side effect must be kept into consideration. The unclear pathophysiologic role of TNFa in ALS and the possibility of neurologic side effects during drugs exposure lead to caution in the clinical practice.
Key message
Concomitant RA and ALS are rare and may be casual. A potential neurotoxicity of TNFa blockers must be considered.
